OMER News and Press, Omeros Corporation From 02/26/19

Omeros Corporation (OMER) has been a real puzzle for years. Some years ago, when its drug Omidria's pass-through status was about to be rescinded, we wrote positively about the stock, saying, one, that they will get back pass-through status, and two, OMS721 is the key (read our previous cover...

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018, on Friday, March 1, 2019, before the market opens. Omeros management will host a conference call and webcast that day ...

Omeros Corporation (Nasdaq: OMER) today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names (USAN) Council, in consultation with the World Health Organization’s International Nonproprietary Names (INN) Expert Committee, has ...

Omeros ( OMER +9.6% ) is up more than double normal volume in response to the news that it has streamlined the work required for its U.S. marketing application seeking approval for OMS721 for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-...

Patient Data from Existing Single-Arm Study Will Form the Basis for BLA; No Historical Control Required Omeros Corporation (Nasdaq: OMER) today announced that, based on a recent meeting with the U.S. Food and Drug Administration (FDA), the company has streamlined the required work and...

-- Former Lilly Biotechnology and Immunology Senior Vice President Drawn by Omeros’ Complement Franchise and Novel-Product Pipeline -- Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol, Ph.D., to its Board of Directors. Dr. Bumol is Executive ...

Omeros Corporation (NASDAQ: OMER ) announces preliminary Q4 2018 revenue. More news on: Omeros Corporation, Healthcare stocks news, Stocks on the move, Read more ...

– Broadening OMIDRIA Coverage from Payers and Increasing Funding for OMS721 Commercial Preparations – Omeros Corporation (Nasdaq: OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018. Omeros’ preliminary...

-- Hires Commercial and CMC Heads from Celgene -- Omeros Corporation (Nasdaq: OMER) today announced that it hired two new senior management team members – Daniel Kirby as vice president and head of commercial and Justin McCue, Ph.D. as vice president of chemistry, manufacturi...

NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Omeros Corporation (NASDAQ:OMER), Apple Inc. (NASDAQ:AAPL), Bio-Rad La...